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Purpose
To describe the demographics, disease features and
treatment of participants with pediatric systemic lupus
erythematosus (pSLE) enrolled to date in the CARRAnet
registry.
Methods
Subjects were included in the CARRAnet registry, a
national pediatric rheumatology database, if diagnosed
with pSLE at ≤16 years of age and ≤ age 21 at enrollment.
Demographics, disease features and prior and current
treatments were collected, as well as the SLE disease activ-
ity index (SLEDAI), Health Related Quality of Life
(HRQOL), ACR Functional Class (current and worst ever),
Childhood Health Assessment Questionnaire (CHAQ),
and Physician Global Assessment of disease activity
(PGA). Associations between parameters were assessed
using Spearman’s coefficient, and linear regression was
used to determine predictors of intravenous (IV) cyclo-
phosphamide (CYC) administration.
Results
Data from 123 participants enrolled at 20 sites were ana-
lyzed; 2 sites contributed 43 participants (35%). Mean age
at onset of symptoms was 13 ± 3yrs (range 3.3-19.9 yrs),
and mean age at enrollment was 16.3 yrs ± 2.9 (range 7.1-
21.4 yrs). 42 subjects (34%) were diagnosed at ≤12 yrs of
age. The cohort was 34.1% white, 40.7% black, 7.3% Asian,
3.3% American Indian, and 14.6% of participants were
classified as ‘other’. 22 participants (17.8%) were Hispanic.
In the prior 6 months, 3.3% (n=4) had pulmonary involve-
ment, 4.0% (n=5) had myocarditis/pericarditis, and 15.4%
(n=19) developed at least 1 of the following: lupus head-
ache, cranial nerve disorder, organic brain syndrome, psy-
chosis and/or seizure. Since diagnosis, 57 participants
(46.3%) underwent renal biopsy, avascular necrosis devel-
oped in 10 (8.1%), and thrombosis in 9 (7.3%). A summary
of medications prescribed are listed in Table 1.
CYC use was not associated with gender, age at onset,
CHAQ score, or ACR Functional Class; but was asso-
ciated with renal biopsy (p<.001 [CI 4.14-30.6]). 56 par-
ticipants (45.5%) were classified as ACR Functional
Class III or IV at some point in their disease course,
while14 (11.4%) were considered Class III or IV at the
time of enrollment. 54 participants (43.9%) rated their
HRQOL as “very good” or “excellent” but physical func-
tion was impaired with CHAQ>0 in 48% (n=59). The
median score for PGA and SLEDAI was 2 (range 0-7)
and 2 (range 0-38), respectively. There was a significant
association between the CHAQ and SLEDAI scores
(rho=0.19, p=0.03) or the PGA (rho=0.26, p=0.04).
Conclusion
In the initial analysis of pSLE subjects in the CARRAnet
registry, most participants required steroids for disease
control and the majority were on additional immuno-
suppressants. Furthermore, disability occurred in nearly
half the cohort, indicating improved treatment strategies
are needed to treat pSLE.
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Table 1 Prescribed treatments in the CARRAnet registry
Medications Ever prescribed N (%) Currently prescribed N (%)
Prednisone 119 (97) 94 (79)
Methylprednisolone (IV) 66 (54) 4 (3)
Hydroxychlorquine 116 (94) 105 (85)
Mycophenolate mofetil 72 (59) 61 (50)
Cyclophosphamide (IV) 60 (49) 10 (8)
Azathioprine 27 (22) 10 (8)
Methotrexate (oral or injectable) 32 (26) 15 (12)
Rituximab 26 (21) 8 (7)
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